| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-827 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6813 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
1998-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_713b12276be4f7c0d3bdbc49df960d5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_727f0feadd43496e8156b50af4146846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdb6fb4344cb5cc3601993c2057f8b7e |
| publicationDate |
2001-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-336720-A |
| titleOfInvention |
A coagulation-deficient tissue factor (TF) compound [e.g. IgG-H6-N'-cys-tTF219] that is at least 100 times less active than the native form and its use against vascular tumour |
| abstract |
A composition comprising a biologically effective amount of a coagulation-deficient Tissue Factor compound that is at least about 100-fold less active than full length, native Tissue Factor and that has been modified to increase its biological half-life; wherein the modification does not consist of attaching the Tissue Factor compound to an antibody or antigen binding region thereof that binds to a diseased cell, a component of disease-associated vasculature or a component of disease-associated stroma. The administration of the composition results in the promotion of coagulation, preferentially, or specifically, in the prothrombotic blood vessels. |
| priorityDate |
1997-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |